atorvastatin indications/contra

Stem definitionDrug idCAS RN
antihyperlipidaemic substances, HMG CoA reductase inhibitors 257 134523-00-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • CI-981
  • CI981
  • atorvastatin calcium hydrate
  • atorvastatin calcium anhydrous
  • atorvastatin
  • atorvastatin acid
  • cardyl
  • atorvastatin calcium
  • atorvastatin calcium trihydrate
A pyrrole and heptanoic acid derivative,HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITOR (statin), and ANTICHOLESTEREMIC AGENT that is used to reduce serum levels of LDL-CHOLESTEROL; APOLIPOPROTEIN B; AND TRIGLYCERIDES and to increase serum levels of HDL-CHOLESTEROL in the treatment of HYPERLIPIDEMIAS and prevention of CARDIOVASCULAR DISEASES in patients with multiple risk factors.
  • Molecular weight: 558.65
  • Formula: C33H35FN2O5
  • CLOGP: 4.46
  • LIPINSKI: 1
  • HAC: 7
  • HDO: 4
  • TPSA: 111.79
  • ALOGS: -5.95
  • ROTB: 12

Drug dosage:

DoseUnitRoute
20 mg O

Approvals:

DateAgencyCompanyOrphan
Dec. 17, 1996 FDA PFIZER

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Myalgia 9152.11 25.37 2587 18528 29488 3335256
Drug hypersensitivity 5622.12 25.37 1830 19285 33850 3330894
Rhabdomyolysis 5547.96 25.37 1507 19608 14222 3350522
Blood creatine phosphokinase increased 3980.04 25.37 1117 19998 11896 3352848
Muscular weakness 2109.54 25.37 768 20347 19573 3345171
Muscle spasms 2026.15 25.37 804 20311 26099 3338645
Drug interaction 1702.79 25.37 839 20276 45973 3318771
Pain in extremity 1674.79 25.37 843 20272 48369 3316375
Myopathy 1577.05 25.37 393 20722 2466 3362278
Blood cholesterol increased 1385.55 25.37 433 20682 6736 3358008
Arthralgia 1296.27 25.37 765 20350 60096 3304648
Asthenia 1273.31 25.37 777 20338 64888 3299856
Alanine aminotransferase increased 1272.67 25.37 557 20558 23083 3341661
Amnesia 1271.47 25.37 448 20667 10278 3354466
Aspartate aminotransferase increased 1163.85 25.37 506 20609 20607 3344137
Liver function test abnormal 1075.39 25.37 416 20699 12485 3352259
Acute kidney injury 979.44 25.37 595 20520 49088 3315656
Myositis 972.11 25.37 260 20855 2225 3362519
Immune-mediated necrotising myopathy 894.25 25.37 158 20957 61 3364683
Fatigue 820.87 25.37 724 20391 106516 3258228
Pain 777.74 25.37 593 20522 70964 3293780
Hepatic enzyme increased 748.01 25.37 326 20789 13299 3351445
Gait disturbance 744.66 25.37 408 20707 27584 3337160
Low density lipoprotein increased 735.59 25.37 196 20919 1648 3363096
Malaise 707.56 25.37 540 20575 64637 3300107
Hepatitis 646.96 25.37 266 20849 9359 3355385
Muscle atrophy 623.31 25.37 174 20941 1770 3362974
Hepatic function abnormal 610.73 25.37 267 20848 10960 3353784
Liver disorder 581.74 25.37 251 20864 9972 3354772
Jaundice 571.34 25.37 247 20868 9860 3354884

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC C10AA05 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, PLAIN
HMG CoA reductase inhibitors
ATC C10BA05 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, COMBINATIONS
HMG CoA reductase inhibitors in combination with other lipid modifying agents
ATC C10BX03 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, COMBINATIONS
HMG CoA reductase inhibitors, other combinations
ATC C10BX06 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, COMBINATIONS
HMG CoA reductase inhibitors, other combinations
ATC C10BX08 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, COMBINATIONS
HMG CoA reductase inhibitors, other combinations
ATC C10BX11 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, COMBINATIONS
HMG CoA reductase inhibitors, other combinations
ATC C10BX12 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, COMBINATIONS
HMG CoA reductase inhibitors, other combinations
ATC C10BX15 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, COMBINATIONS
HMG CoA reductase inhibitors, other combinations
FDA EPC N0000175589 HMG-CoA Reductase Inhibitor
MeSH PA D000924 Anticholesteremic Agents
MeSH PA D000963 Antimetabolites
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D019161 Hydroxymethylglutaryl-CoA Reductase Inhibitors
MeSH PA D000960 Hypolipidemic Agents
MeSH PA D057847 Lipid Regulating Agents

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Hypercholesterolemia indication 13644009
Arteriosclerotic vascular disease indication 72092001 DOID:2349
Prinzmetal angina indication 87343002
Angina pectoris indication 194828000
Cerebrovascular accident indication 230690007 DOID:6713
Familial hypercholesterolemia - homozygous indication 238078005
Familial hypercholesterolemia - heterozygous indication 238079002
Mixed hyperlipidemia indication 267434003
Hypertriglyceridemia indication 302870006
Familial type 3 hyperlipoproteinemia indication 398796005 DOID:3145
Myocardial Infarction Prevention indication
Slow Progression of Coronary Artery Disease indication
Primary Prevention of Coronary Heart Disease indication
Alcoholism contraindication 7200002
Hypothyroidism contraindication 40930008 DOID:1459
Low blood pressure contraindication 45007003
Hepatic failure contraindication 59927004
Chronic idiopathic constipation contraindication 82934008
Kidney disease contraindication 90708001 DOID:2527
Disorder of muscle contraindication 129565002 DOID:423
Liver function tests abnormal contraindication 166603001
Hemorrhagic cerebral infarction contraindication 230706003
Disease of liver contraindication 235856003 DOID:409
Rhabdomyolysis contraindication 240131006
Pregnancy, function contraindication 289908002
Surgical procedure contraindication 387713003
Breastfeeding (mother) contraindication 413712001
Traumatic injury contraindication 417746004
Severe Aortic Valve Stenosis contraindication
Prevention of Transient Ischemic Attacks off-label use

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.44 acidic
pKa2 11.82 acidic
pKa3 13.63 acidic

Orange Book patent data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 10MG BASE CADUET PFIZER N021540 Jan. 30, 2004 RX TABLET ORAL 6455574 Aug. 11, 2018 TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION
EQ 20MG BASE CADUET PFIZER N021540 Jan. 30, 2004 RX TABLET ORAL 6455574 Aug. 11, 2018 TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION
EQ 40MG BASE CADUET PFIZER N021540 Jan. 30, 2004 RX TABLET ORAL 6455574 Aug. 11, 2018 TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION
EQ 80MG BASE CADUET PFIZER N021540 Jan. 30, 2004 RX TABLET ORAL 6455574 Aug. 11, 2018 TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION

Orange Book exclusivity data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 10MG BASE LIPITOR PFIZER N020702 Dec. 17, 1996 RX TABLET ORAL June 23, 2020 CLINICAL INFORMATION ADDED TO THE PACKAGE INSERT REGARDING USE OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS AGES 10-17 WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)
EQ 20MG BASE LIPITOR PFIZER N020702 Dec. 17, 1996 RX TABLET ORAL June 23, 2020 CLINICAL INFORMATION ADDED TO THE PACKAGE INSERT REGARDING USE OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS AGES 10-17 WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
3-hydroxy-3-methylglutaryl-coenzyme A reductase Enzyme INHIBITOR IC50 8 WOMBAT-PK CHEMBL
Nuclear receptor subfamily 1 group I member 3 Nuclear hormone receptor WOMBAT-PK
Cytochrome P450 3A4 Enzyme IC50 5.29 CHEMBL
Histone deacetylase 6 Enzyme IC50 4.84 CHEMBL
Histone deacetylase 1 Enzyme IC50 4.93 CHEMBL
Histone deacetylase 2 Enzyme IC50 4.65 CHEMBL
3-hydroxy-3-methylglutaryl-coenzyme A reductase Enzyme IC50 8.42 CHEMBL
3-hydroxy-3-methylglutaryl-coenzyme A reductase Enzyme IC50 4.49 CHEMBL

External reference:

scroll-->
IDSource
2949 IUPHAR_LIGAND_ID
4024041 VUID
N0000022046 NUI
C0286651 UMLSCUI
D00887 KEGG_DRUG
48A5M73Z4Q UNII
344423-98-9 SECONDARY_CAS_RN
DB01076 DRUGBANK_ID
4024041 VANDF
N0000022046 NDFRT
006321 NDDF
d04105 MMSL
4226 MMSL
83367 RXNORM
108600003 SNOMEDCT_US
373444002 SNOMEDCT_US
7259 INN_ID
CHEMBL393220 ChEMBL_ID
CHEMBL1487 ChEMBL_ID
60823 PUBCHEM_CID
CHEMBL1790017 ChEMBL_ID
D000069059 MESH_DESCRIPTOR_UI
CHEBI:39548 CHEBI
117 PDB_CHEM_ID

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
Caduet HUMAN PRESCRIPTION DRUG LABEL 2 0069-2150 TABLET, FILM COATED 10 mg ORAL NDA 19 sections
Caduet HUMAN PRESCRIPTION DRUG LABEL 2 0069-2160 TABLET, FILM COATED 10 mg ORAL NDA 19 sections
Caduet HUMAN PRESCRIPTION DRUG LABEL 2 0069-2170 TABLET, FILM COATED 20 mg ORAL NDA 19 sections
Caduet HUMAN PRESCRIPTION DRUG LABEL 2 0069-2180 TABLET, FILM COATED 20 mg ORAL NDA 19 sections
Caduet HUMAN PRESCRIPTION DRUG LABEL 2 0069-2190 TABLET, FILM COATED 40 mg ORAL NDA 19 sections
Caduet HUMAN PRESCRIPTION DRUG LABEL 2 0069-2250 TABLET, FILM COATED 40 mg ORAL NDA 19 sections
Caduet HUMAN PRESCRIPTION DRUG LABEL 2 0069-2260 TABLET, FILM COATED 80 mg ORAL NDA 19 sections
Caduet HUMAN PRESCRIPTION DRUG LABEL 2 0069-2270 TABLET, FILM COATED 80 mg ORAL NDA 19 sections
Caduet HUMAN PRESCRIPTION DRUG LABEL 2 0069-2960 TABLET, FILM COATED 10 mg ORAL NDA 19 sections
Caduet HUMAN PRESCRIPTION DRUG LABEL 2 0069-2970 TABLET, FILM COATED 20 mg ORAL NDA 19 sections
Caduet HUMAN PRESCRIPTION DRUG LABEL 2 0069-2980 TABLET, FILM COATED 40 mg ORAL NDA 19 sections
Lipitor HUMAN PRESCRIPTION DRUG LABEL 1 0071-0155 TABLET, FILM COATED 10 mg ORAL NDA 18 sections
Lipitor HUMAN PRESCRIPTION DRUG LABEL 1 0071-0156 TABLET, FILM COATED 20 mg ORAL NDA 18 sections
Lipitor HUMAN PRESCRIPTION DRUG LABEL 1 0071-0157 TABLET, FILM COATED 40 mg ORAL NDA 18 sections
Lipitor HUMAN PRESCRIPTION DRUG LABEL 1 0071-0158 TABLET, FILM COATED 80 mg ORAL NDA 18 sections
Atorvastatin Calcium HUMAN PRESCRIPTION DRUG LABEL 1 0093-5056 TABLET, FILM COATED 10 mg ORAL ANDA 17 sections
Atorvastatin Calcium HUMAN PRESCRIPTION DRUG LABEL 1 0093-5057 TABLET, FILM COATED 80 mg ORAL ANDA 17 sections
Atorvastatin Calcium HUMAN PRESCRIPTION DRUG LABEL 1 0093-5058 TABLET, FILM COATED 40 mg ORAL ANDA 17 sections
Atorvastatin Calcium HUMAN PRESCRIPTION DRUG LABEL 1 0093-5059 TABLET, FILM COATED 20 mg ORAL ANDA 17 sections
ATORVASTATIN CALCIUM HUMAN PRESCRIPTION DRUG LABEL 1 0179-0141 TABLET, FILM COATED 80 mg ORAL NDA AUTHORIZED GENERIC 19 sections
ATORVASTATIN CALCIUM HUMAN PRESCRIPTION DRUG LABEL 1 0179-0214 TABLET, FILM COATED 40 mg ORAL NDA AUTHORIZED GENERIC 19 sections
ATORVASTATIN CALCIUM HUMAN PRESCRIPTION DRUG LABEL 1 0179-0215 TABLET, FILM COATED 20 mg ORAL NDA AUTHORIZED GENERIC 19 sections
ATORVASTATIN CALCIUM HUMAN PRESCRIPTION DRUG LABEL 1 0179-0216 TABLET, FILM COATED 10 mg ORAL NDA AUTHORIZED GENERIC 19 sections
Atorvastatin Calcium HUMAN PRESCRIPTION DRUG LABEL 1 0378-3950 TABLET, FILM COATED 10 mg ORAL ANDA 18 sections
Atorvastatin Calcium HUMAN PRESCRIPTION DRUG LABEL 1 0378-3951 TABLET, FILM COATED 20 mg ORAL ANDA 18 sections
Atorvastatin Calcium HUMAN PRESCRIPTION DRUG LABEL 1 0378-3952 TABLET, FILM COATED 40 mg ORAL ANDA 18 sections
Atorvastatin Calcium HUMAN PRESCRIPTION DRUG LABEL 1 0378-3953 TABLET, FILM COATED 80 mg ORAL ANDA 18 sections
Amlodipine besylate and atorvastatin calcium HUMAN PRESCRIPTION DRUG LABEL 2 0378-4510 TABLET, FILM COATED 10 mg ORAL ANDA 18 sections
Amlodipine besylate and atorvastatin calcium HUMAN PRESCRIPTION DRUG LABEL 2 0378-4511 TABLET, FILM COATED 20 mg ORAL ANDA 18 sections
Amlodipine besylate and atorvastatin calcium HUMAN PRESCRIPTION DRUG LABEL 2 0378-4512 TABLET, FILM COATED 40 mg ORAL ANDA 18 sections